This is the first in a series of practice guidelines commissioned by the Infectious Diseases
Society of America through its Practice Guidelines Committee. The purpose of these …

Purpose Current treatment for febrile neutropenia (FN) includes hospitalization for
evaluation, empiric broad-spectrum antibiotics, and other supportive care. Clinical trials …

BACKGROUND Hospitalization for febrile neutropenia (FN) in cancer patients is associated
with considerable morbidity, mortality, and cost. The study was undertaken to better define …

This article, prepared by the Infectious Diseases Society of America (IDSA) Fever and
Neutropenia Guidelines Panel, updates guidelines established a decade ago by the …

Clin Microbiol Infect 2012; 18 (Suppl. 7): 53–67 Abstract Fungal diseases still play a major
role in morbidity and mortality in patients with haematological malignancies, including those …

2000 update of recommendations for the use of hematopoietic colony-stimulating factors:
evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth …

The prognostic significance of major organ and tissue infection was examined in 909
episodes of bacteremia that were selected from 10 consecutive, randomized clinical trials of …

Neutropenia and its subsequent infectious complications represent the most common dose-
limiting toxicity of cancer chemotherapy. Febrile neutropenia (FN) occurs with common …

Background Febrile neutropenia is a frequent adverse event experienced by people with
cancer who are undergoing chemotherapy, and is a potentially life‐threatening situation …

Background Randomized trials of colony-stimulating factors in febrile patients with
neutropenia after chemotherapy have not consistently shown clinical benefit. Nevertheless …